Scarica l'app Stockscreener
3.245
0.46%
0.015
Dopo l'orario di chiusura:
3.33
0.085
+2.62%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Pds Biotechnology Corporation Borsa (PDSB) Ultime notizie
Contrasting Semiconductor Manufacturing International (OTCMKTS:SMICY) & POET Technologies (NASDAQ:POET) - Defense World
StockNews.com Initiates Coverage on Ark Restaurants (NASDAQ:ARKR) - Defense World
Jones Soda Announces Departure of President and CEO, David Knight, and Appointment of Interim CEO, Paul Norman - Defense World
Mastech Digital (NYSE:MHH) Coverage Initiated by Analysts at StockNews.com - Defense World
Head-To-Head Analysis: Edison International (NYSE:EIX) and AltC Acquisition (NYSE:ALCC) - Defense World
FS KKR Capital Corp. (NYSE:FSK) Given Consensus Rating of “Hold” by Brokerages - Defense World
StockNews.com Begins Coverage on TRX Gold (NYSE:TRX) - Defense World
Mastech Digital (NYSE:MHH) Now Covered by Analysts at StockNews.com - Defense World
PDS Biotechnology Co. (NASDAQ:PDSB) Receives $14.25 Consensus Price Target from Analysts - MarketBeat
Bowhead Specialty (NYSE:BOW) versus Horace Mann Educators (NYSE:HMN) Critical Survey - Defense World
Zacks Research Issues Negative Estimate for CSX Earnings - Defense World
Hillman Solutions (HLMN) to Announce Quarterly Earnings on Tuesday - Defense World
Evolv Technology Holdings CEO terminated, replaced by Michael Ellenbogen as Interim CEO - Defense World
Chase (NYSE:CCF) Now Covered by Analysts at StockNews.com - Defense World
PDS Biotechnology (NASDAQ:PDSB) Stock Rating Upgraded by StockNews.com - MarketBeat
HC Wainwright Reaffirms Buy Rating for PDS Biotechnology (NASDAQ:PDSB) - MarketBeat
Is There More Room To Run For This Immunotherapy Company Stock After Hitting New High? - RTTNews
PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine - The Manila Times
NY Biopharma Shares Promising Clinical Data - Streetwise Reports
Data Readouts At ASCO (MRUS, ORIC, CGEN, PDSB...) - RTTNews
H.C. Wainwright & Co. Shares Buy Rating on Biotech Co. - Streetwise Reports
PDS Biotechnology Co. (NASDAQ:PDSB) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Europe Aneurysmal Subarachnoid Hemorrhage Drugs Market Size, Spotlight on Future Potentials (2024-2034) - IndiaPolitics.com
CD47 Inhibitors Market Projected to Grow Significantly with Emerging Cancer Therapies by 2034 | DelveInsight - The Malaysian Reserve
Mass. Biotech Receives FDA Approval - Streetwise Reports
PDS Biotechnology Corporation: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
PDS Biotechnology Corporation (PDSB)’s stock price range in the last year - US Post News
Capsule Filler Machine Industry to Eyewitness Massive Growth - Elektrotransports.lv
Major Improvements In Hershey Company (HSY) Stock Need To Be Considered - Stocks Register
Biotech Alert: Searches spiking for these stocks today - TipRanks
PDS Biotechnology shares maintain Buy rating from H.C. Wainwright on positive trial results By Investing.com - Investing.com South Africa
PDS Biotechnology shares maintain Buy rating from H.C. Wainwright on positive trial results - Investing.com India
Biotech Completes Last Patient Visit in Phase2b Osteosarcoma Trial - Streetwise Reports
Investor’s Delight: PDS Biotechnology Corporation (PDSB) Closes Strong at 4.11, Up 12.60 - The Dwinnex
XTX Topco Ltd Invests $57,000 in 3D Systems Co. (NYSE:DDD) - Defense World
Locally Advanced Cervical Cancer Phase 2 Study Publishes Positive Results - Precision Vaccinations
PDS Biotech reports promising phase 2 cervical cancer trial results By Investing.com - Investing.com Canada
PDS Biotech reports promising phase 2 cervical cancer trial results - Investing.com
New Jersey Biotech Reports Positive Survival Data - Streetwise Reports
This trade activity should not be overlooked: PDS Biotechnology Corporation (PDSB) - SETE News
PDS Biotechnology (NASDAQ:PDSB) Given "Buy" Rating at HC Wainwright - MarketBeat
PDS Biotechnology’s Versamune® HPV Shows Promise in Phase 2 Trial - TipRanks
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation - The Manila Times
PDSB’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
A venture capital company on a huge discount - Investors Chronicle
PDSB’s current quarter earnings: What analysts forecast? - US Post News
Three North Jersey startup tech firms get aid through state program - NorthJersey.com
Three North Jersey startup tech firms get state financing for R&D and salaries - Daily Record
What's Going On With Vistra Stock? - MSN
PDS Biotechnology: Continuing The Holding Pattern (NASDAQ:PDSB) - Seeking Alpha
PDS Biotechnology (NASDAQ:PDSB) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
PDS: Updated Results, VERSATILE-002 Phase 2 Trial - ShareCast
PDS Biotech Advances with Promising Versamune® HPV Trial Results - TipRanks
PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024 - StockTitan
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):